AICAR (phosphate) (Standard)

• Description:

  AICAR (phosphate) (Standard) is the analytical standard of AICAR (phosphate) . This product is intended for research and analytical applications. AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor[1][2].

• UNSPSC:

  12352100

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  AMPK; Autophagy; Endogenous Metabolite; Mitophagy; Reference Standards; YAP

• Related Pathways:

  Autophagy; Epigenetics; Metabolic Enzyme/Protease; Others; PI3K/Akt/mTOR; Stem Cell/Wnt

• Field of Research:

  Cancer

• Purity:

  99.98

• Smiles:

  OC[C@@H]1[C@@H] (O) [C@@H] (O) [C@H] (N2C=NC (C (N) =O) =C2N) O1.O=P (O) (O) O

• Molecular Formula:

  C9H17N4O9P

• Molecular Weight:

  356.23

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Nakamaru K, et al. AICAR, an activator of AMP-activated protein kinase, down-regulates the IR expression in HepG2 cells. Biochem Biophys Res Commun. 2005 Mar 11;328 (2) :449-54|[2]Drake JC, et al. AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2010 Dec;299 (6) :R1546-54.|[3]Pold R, et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats.Diabetes. 2005 Apr;54 (4) :928-34.|[4]Giri S, et al. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004 Jan 14;24 (2) :479-87.|[5]Ajaybabu V Pobbati, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10 (8) :3622-3635.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  4°C, sealed storage, away from light and moisture

• Scientific Category:

  Reference Standards

• Clinical Information:

  No Development Reported

• CAS Number:

  681006-28-0